Rennova Health Inc (RNVA)

[jmoney360]

Item 1.01 Entry Into a Material Definitive Agreement



On March 20, 2024, Rennova Health, Inc. (the “Company”) and certain institutional holders agreed that, with respect to Series B Warrants (originally issued on March 21, 2017), to acquire 101,350,000,000 shares of common stock, the termination date of such warrants would be extended from March 21, 2024 to December 31, 2025; provided, that (subject to the Company then having an effective registration statement covering the applicable number of shares), if Series B Warrants to acquire the following number of shares of common stock are not exercised in the respective periods below (each, an “Exercise Condition”), the termination date of all of the Series B Warrants shall instead be the date the first such Exercise Condition is not satisfied:




From March 21, 2024 to April 15, 2024 1,350,000,000 shares
From April 16, 2024 to August 30, 2024 2,500,000,000 shares
From August 31, 2024 to December 27, 2024 4,000,000,000 shares
From December 28, 2024 to April 24, 2025 4,000,000,000 shares
From April 25, 2025 to August 29, 2025 4,000,000,000 shares


Such share numbers are subject to adjustment in the case of stock splits, combinations, dividends, reclassifications, recapitalizations or other similar events. No cashless exercise of Series B Warrants shall count toward the satisfaction of an Exercise Condition. Other than the Series B Warrants to acquire 101,350,000,000 shares of common stock extended pursuant to the terms of this agreement, warrants to acquire the following number of shares of common stock held by the institutional holders expired on March 21, 2024 pursuant to their terms: Series A Warrants (189,968,328,333 shares); Series B Warrants (23,852,257,133 shares); and Series C Warrants (189,968,321,178 shares). The Company issued a press release on March 26, 2024 announcing the above warrant extension and expirations, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.